Cellectar biosciences stock
The 3 analysts offering 12-month price forecasts for Cellectar Biosciences Inc have a median target of 6.40, with a high estimate of 10.00 and a low estimate of 15 May 2019 Cellectar is a New Jersey clinical-stage biopharmaceutical company focused on developing and bringing to market cancer treatments. Its CLR Stock analysis for Cellectar Biosciences Inc (CLRB:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company The Cellectar Biosciences stock price is 1.190 USD today. Will Cellectar Biosciences stock price grow / rise / go up? Yes. The CLRB stock price can go up from 25 Feb 2020 If you follow Cellectar Biosciences (NASDAQ: CLRB), you've seen a pretty rough few days. In fact, over this period, the stock has given up In depth view into CLRB (Cellectar Biosciences) stock including the latest price, news, dividend history, earnings information and financials. Stock screener for investors and traders, financial visualizations.
Sep 06, 2019 · Cellectar Biosciences (NASDAQ:CLRB) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
Feb 19, 2020 · Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for … Analyzing Cellectar Biosciences (NASDAQ:CLRB) & Kadmon ... Kadmon (NYSE:KDMN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, … Cellectar Biosciences Inc. Stock Price (CLRB) | Barron's View today's stock price, news and analysis for Cellectar Biosciences Inc. (CLRB). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation Cellectar Biosciences (CLRB) Stock: A Compelling ...
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer
Discover historical prices for CLRB stock on Yahoo Finance. View daily, weekly or monthly format back to when Cellectar Biosciences, Inc. stock was issued. Cellectar Biosciences, Inc. Common Stock (CLRB) Earnings ... Mar 31, 2020 · Cellectar Biosciences, Inc. is estimated to report earnings on 05/04/2020. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Cellectar Biosciences, Inc. (CLRB) Interactive Stock Chart ... Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update. FLORHAM PARK, N.J., March 09, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical CLRB | Cellectar Biosciences Inc. Stock Price & News - WSJ
Cellectar Biosciences Inc. Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease;
Product Pipeline :: Cellectar Biosciences, Inc. (CLRB) Multi-Asset Product Portfolio for Treatment of Various Cancers. Our proprietary phospholipid ether (PLE) platform technology features include the capacity to link to a wide variety of warheads, provide a significant increase in targeted oncologic warhead delivery and the ability to target all tumor cells. Analyzing Cellectar Biosciences (NASDAQ:CLRB) & Kadmon ...
The Cellectar Biosciences stock price is 1.190 USD today. Will Cellectar Biosciences stock price grow / rise / go up? Yes. The CLRB stock price can go up from
Split History. Stock splits are used by Cellectar Biosciences, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a View CLRB stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. Cellectar Biosciences, Inc. (the Company) is a clinical stage biopharmaceutical company focused on the development of targeted phospholipid drug conjugates 15 Aug 2014 Cellectar Biosciences, a Madison, WI-based startup developing cancer drugs and imaging tools, began trading on the Nasdaq stock exchange Cellectar Biosciences (Nasdaq: CLRB) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and 13 Sep 2019 Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ: CLRB) with a “buy” rating and $11 price target. The stock closed
DOCRF vs. CLRB Stock Research Comparison